ABVX

Jefferies downgraded Abivax SA from Buy to Hold and set a new price target of $90.00

Wedbush upgraded Abivax SA from Underperform to Neutral and set a new price target of $90.00

6-K - Abivax S.A. (0001956827) (Filer)

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis At Week 44, both the 25 mg and 50 mg once-daily obefazimod doses met the primary endpoint, demonstrating placebo-adjusted clinical remission rates of ∆39.3% and ∆40.3%, respectively (25 mg: 50.8%, 50 mg: 51.3% vs placebo 10.4%; p<0.0001)Both 25 mg and 50 mg obefazimod met all key secondary endpoints, demonstrating robust and clinically meaningful efficacy results across multiple measures of disease controlObefazimod demonstrated a favorable safety profile over the 44-week maintenance trial (N=580), with no new safety signalsRecently reported Phase 2a/2

DENVER, May 28, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Biotechnology has always been a sector driven by inflection points, and few milestones matter more than Phase 2 clinical data. For emerging biotech companies, Phase 2 is often the moment when science transitions from theory to validation. It is where investors, analysts, pharmaceutical partners, and institutional capital begin to separate promising platforms from speculative concepts. Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store That is why so much attention is focused on companies that are approaching pivotal readouts or are fresh off meaningful Phase 2 updates that could materially

6-K - Abivax S.A. (0001956827) (Filer)

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis Interim intent to treat ("ITT") analysis from Study 108 supports strong durable clinical remission in moderately to severely active ulcerative colitis ("UC") patients treated with obefazimodFollowing two to four years of open-label treatment with 50 mg, 130 patients de-escalated to 25 mg, and at week 144, 68% (88/130) were in clinical remission and 80% (104/130) completed 144 weeks of treatmentPatients in Study 108 were treated with obefazimod for up to seven years, wit

6-K - Abivax S.A. (0001956827) (Filer)

Abivax Announces Results of its May 11, 2026 Annual General Meeting PARIS, France – May 11, 2026 – 10:05 pm CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, held its annual general meeting of shareholders on May 11, 2026 (the "General Meeting"), which was chaired by Ms. Sylvie Grégoire, Chair of the Board of Directors of Abivax (the "Board"). The shareholders have adopted all the resolutions proposed by the Board, and particularly the financial statements for the

SCHEDULE 13D/A - Abivax S.A. (0001956827) (Subject)

6-K - Abivax S.A. (0001956827) (Filer)

424B7 - Abivax S.A. (0001956827) (Filer)

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares Cash runway remains into Q4 2027, supporting continued funding of clinical programs and pre-commercial planning activitiesRoyalty overhang materially reduced, enhancing financial flexibility to support future commercialization efforts PARIS, France – May 5, 2026 – 8:00 am CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces (i) the execution of a p

Abivax to Present Data on Obefazimod at Digestive Disease Week® Presentations Highlight Comprehensive Efficacy, Safety, and Patient-Reported Outcomes from the Phase 3 ABTECT Program and Preclinical Anti-Fibrotic Models in Inflammatory Bowel Disease PARIS, France – April 22, 2026 – 10:05 pm CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that nine scientific abstracts on obefazimod, its lead drug candidate for the treatment of moderately to severel

6-K - Abivax S.A. (0001956827) (Filer)

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026Availability of the Preparatory Documents PARIS, France, April 20, 2026, 10:05 PM CEST – Abivax SA ((Euronext Paris &, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, informs its shareholders that its ordinary and extraordinary general meeting (the "General Meeting") will be held on May 11, 2026, at 3:00 pm (CEST), at the hotel Paris Marriott Opera Ambassador, located at 16 boulevard Haussmann in Paris (75009), France.

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – April 1, 2026 – 10:05 PM CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"),  a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d'Enregistrement Universel) with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), and the fili

S-8 - Abivax S.A. (0001956827) (Filer)

20-F - Abivax S.A. (0001956827) (Filer)

6-K - Abivax S.A. (0001956827) (Filer)

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis included 100% of patients randomized, with nearly 90% having completed the 44-week double blind maintenance trialThe Company's pivotal Phase 3 ABTECT maintenance trial evaluating obefazimod for moderately to severely active ulcerative colitis remains on track to report topline results in late Q2 2026Abivax appointed Michael Nesrallah, MBA as Chief Commercial Officer, bringing extensive IBD leadership experience to support the Company's next phase of growth; other key senior leadership hires made

Jefferies initiated coverage of Abivax SA with a rating of Buy and set a new price target of $160.00

Wedbush initiated coverage of Abivax SA with a rating of Outperform and set a new price target of $110.00

6-K - Abivax S.A. (0001956827) (Filer)

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 22 abstracts presented at European Crohn's and Colitis Organization's (ECCO) 21st Annual Congress illustrate the depth and breadth of data supporting obefazimod's potential in inflammatory bowel diseaseAnti-fibrotic effects of obefazimod were observed in both a preclinical human fibroblast model and in an in vivo animal model, suggesting potential to address a major unmet need in Crohn's diseaseA pooled analysis of safety data from ABTECT-1 and ABTECT-2 induction trials demonstrates a favorable safety profile with rates of ser